Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06288360
Other study ID # NACI-CERV-002
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 1, 2024
Est. completion date December 12, 2030

Study information

Verified date February 2024
Source Tongji Hospital
Contact Kezhen Li
Phone 086-027-8362
Email tjkeke@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.


Description:

This multicenter, prospective, single-arm clinical trial is designed to enroll patients with PD-L1-negative locally advanced cervical cancer with 1 course of priming neoadjuvant chemotherapy followed by 2 courses of neoadjuvant immunochemotherapy, to clarify the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on tumor remission rate, surgical complications, and surgical cleanliness, and to evaluate the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on the survival of patients with locally advanced cervical cancer, to clarify the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on tumor remission rate, surgical complications, and complete resection rate, and to assess the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on the survival of patients with locally advanced cervical cancer, and to explore the changes of local immune-related factors and tumor cells during the treatment process, as well as biomarkers that affect the efficacy of PD-1 combination therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 12, 2030
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. FIGO 2018 stage IB3, IIA2, or IIB (tumor size=4cm) cervical cancer and without any treatment (After undergoing gynecological examinations by two associate chief physicians or above, the staging of the patients was determined); 2. Has at least one measurable lesion based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. In principle, the size of the lesion as shown by the magnetic resonance imaging examination is used as the criterion. 3. Histologically confirmed squamous carcinoma, adenocarcinoma (common type) or adenosquamous carcinoma of the cervix; 4. Negative PD-L1 expression on preoperative pathological examination (Combined positive score < 1); 5. 18-70 years of age; 6. Eastern Cooperative Oncology Group score = 1; 7. WBC=3.5*10^9/L, NEU=1.5*10^9/L, Platelet=100×10^9 /L; AST and ALT =1.5 times normal upper limit; Total bilirubin =1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen =the upper limit of normal value; 8. Well-compliance and willing to keep in touch; 9. Willing to participate in this study, sign the informed consent, and comply with the requirements and limitations outlined in the Informed Consent Form (ICF) and this form. Exclusion Criteria: 1. Active, known, or suspected autoimmune disease, or a history of an autoimmune disease, except for the following: vitiligo, alopecia areata, Graves's disease, psoriasis, or eczema that has not required systemic therapy within the last 2 years, hypothyroidism that is asymptomatic or requires only stable doses of hormone replacement therapy (due to autoimmune thyroiditis), type 1 diabetes that requires only stable doses of insulin replacement therapy, asthma that subsides completely in childhood and does not require intervention in adulthood, or diseases that do not recur in the absence of external triggers; 2. Prior treatment with immune checkpoint inhibitors, including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or antibodies against immune co-stimulators (e.g., antibodies against ICOS, CD40, CD137, GITR, OX40 targets, etc.), or any other therapy targeting a tumor's immune mechanism of action; 3. Known hypersensitivity to any component and/or any excipient of the trial prescribed medication; 4. Immunosuppressive drugs or systemic corticosteroids for immunosuppression (> mg/day of prednisone or other equivalent) within 2 weeks prior to trial dosing; topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are permitted; 5. Received herbs with antitumor effects or drugs with immunomodulatory effects (e.g., thymidine, interferon, interleukin-2) within 2 weeks prior to the trial; 6. Active systemic infection requiring systemic treatment; 7. Serious infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; 8. Patients with untreated chronic hepatitis B, or HBV carriers with chronic hepatitis B virus (HBV) DNA greater than 1,000 IU/mL, or patients with active hepatitis C. Inactive HBsAg carriers, patients with hepatitis B who have received treatment and are in stable condition (HBV < 1000 IU/mL), and patients with cured hepatitis C are eligible for enrollment. HCV antibody-positive subjects will be eligible for the study only if they have a negative HCV RNA test; 9. Known active tuberculosis (TB), patients with suspected active TB should undergo chest X-ray and sputum examination in conjunction with clinical signs and symptoms for exclusion; 10. Immunodeficiency or human immunodeficiency virus (HIV antibody positive); 11. Subjects with active inflammatory bowel disease or a history of such disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea). Subjects who are unable to swallow or who have malabsorption syndrome, uncontrolled nausea, vomiting, diarrhea, or other gastrointestinal disorders that severely interfere with drug intake and absorption; 12. Known interstitial lung disease that is symptomatic or may interfere with detection or treatment of immune-associated pneumonia; 13. Treatment with a live or attenuated vaccine administered within 4 weeks prior to the first trial dose, inactivated seasonal influenza virus vaccine is permitted; 14. Have received a prior allogeneic bone marrow transplant or solid organ transplant; 15. History of primary malignant tumor within the last 5 years; 16. Have undergone major surgery (e.g., open abdomen, open chest, organ resection, etc.) and severe trauma within 28 days prior to the first dose of the implantable infusion device is permitted; 17. With a history of gastrointestinal perforation, gastrointestinal fistula, or female genital fistula; 18. Uncontrolled other co-morbidities, symptoms, or medical history, including (i) persons with one of the following cardiovascular diseases or cardiovascular risk factors: myocardial infarction, unstable angina, pulmonary embolism, acute/continuous myocardial ischemia, cerebral vascular accident, transient ischemic attack, or other arterial or venous thrombosis, embolism, or cerebral ischemic event of clinical significance/requiring pharmacologic intervention; and persons who have had, within 6 months, a symptoms of congestive heart failure (New York Heart Association (NYHA) class III and above); (ii) clinically significant bleeding symptoms or a history of significant bleeding characteristics such as gastrointestinal bleeding, gastric ulcer bleeding, or vasculitis within 1 month prior to the first dose; (iii) clinically active hemoptysis, active diverticulitis, abdominal abscesses, and gastrointestinal obstruction; and (iv) uncontrolled pleural effusion, pericardial effusion, or ascites requiring Repeated drainage of ascites; ? Abnormal liver or kidney development or history of surgery; 19. Pregnant or breastfeeding female patients; women of childbearing age who refuse to accept contraceptive measures during neoadjuvant immunotherapy; 20. Concurrent participation in other interventional clinical trials; participation in observational and non-interventional clinical trials is permitted; 21. Any condition that, in the judgment of the investigator, may result in risk in the receipt of the study drug or that would interfere with the evaluation of the safety of the study drug or the interpretation of the study results. Patients who, in the judgment of the Investigator, are unlikely to comply with the study steps, restrictions, and requirements are not permitted to participate in this study.

Study Design


Intervention

Drug:
Camrelizumab
200 mg, intravenously, 20-60 min. 2 times, every 21 days
Paclitaxel-albumin
260 mg/m² over 30 min, 3 times, every 21 days
Cisplatin
4 h, 75-80 mg/m², 3 times, every 21 days
Procedure:
radical surgery
Radical hysterectomy + pelvic lymphadenectomy ? para-aortic lymphadenectomy

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (14)

Lead Sponsor Collaborator
Tongji Hospital Anhui Provincial Cancer Hospital, Beijing Friendship Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Qilu Hospital of Shandong University, Shengjing Hospital, Sichuan Cancer Hospital and Research Institute, Southwest Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Tianjin Medical University General Hospital, West China Second University Hospital, Women Hospital, School of Medicine, Zhejiang University, Xiangya Hospital of Central South University, Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologic complete response Pathologic complete response (PCR) refers to the absence of invasive/in situ cancer in the uterine cervix and/or lymph nodes undergoing surgery; up to 2 years.
Secondary Surgical Complications Intraoperative bleeding, vascular injuries, bladder injuries, rectal injuries, and ureteral injuries were measured by the need for suture repair; occlusive nerve injuries were measured by complete severance, and vascular injuries required documentation of the site of injury. Postoperative complications included: cervical stenosis, cervical insufficiency, ureteral/bladder/rectal/vaginal fistula, internal hemorrhage, pelvic infection, lymphocyst, lymphatic fistula, lower extremity edema, lower extremity venous thrombosis, urinary retention, nerve injury, and bowel obstruction. during and after surgery; an average of 3 years.
Secondary Objective response rate the proportion of patients who had either complete response or partial response, assessed by independent central reviewers according to RECIST, version 1.1. 3 weeks after the last dose of neoadjuvant treatment and before surgery, up to 2 years.
Secondary Positive surgical margin rate A positive surgical margin means that cancer cells are present at the edge of the resection specimen. undergoing surgery; an average of 2 years
Secondary event-free survival Event-free survival (EFS) refers to the possibility of experiencing a defined set of events (including progression such as metastasis, death, etc.) following NACI treatment designed to delay or prevent that set of events. through study completion, 5 years
Secondary overall survival the time from randomization to death through study completion, 5 years
Secondary adverse event an event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state. throughout the experiment, up to 5 years.
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A